Hjem › Metastatisk kreft › Alabama
Kliniske studier for Metastatisk kreft i Alabama
13 studier for Metastatisk kreft søker deltakere på steder i Alabama.
Byer i Alabama
Offisiell studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05564377Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Clearview Cancer Institute, Huntsville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07562152PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05868226Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- The University of Alabama at Birmingham, Birmingham
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06943755A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- The Kirklin Clinic of UAB Hospital, Birmingham
- The University of Alabama at Birmingham, Birmingham
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06989437A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06103864A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Alabama at Birmingham, Birmingham
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213804CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT07335497A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Clearview Cancer Institute, Huntsville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- University of Alabama at Birmingham Cancer Center, Birmingham
RekruttererFase 1
36 Months – 22 Years · Alle kjønn · Oppdatert 4. sep. 2026 · NCT03911388A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT04657068LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Central Alabama Research, Birmingham
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. jun. 2026 · NCT06216301SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.